Editorial note: This is a regulatory and clinical analysis for educational purposes. It is not medical advice. GLP-1 medications — both compounded and FDA-approved finished products — are prescription only and require evaluation by a licensed clinician. Compounded medications are not FDA-approved finished drugs.
The most important question for anyone considering a compounded GLP-1 telehealth program in May 2026 isn't about results. It's about supply chain.
Two days before this article was written — on April 30, 2026 — the FDA formally proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. The proposal carries direct implications for how platforms like Novi can source the medications they prescribe. To understand what that means, the regulatory categories themselves need to be clear.
This article walks through the actual differences between compounded and brand-name GLP-1 medications, what 503A and 503B compounding mean, where Novi sits inside that framework, and how to ask the right diligence questions before committing to any compounded-GLP-1 telehealth program.
Brand-Name GLP-1 Medications: The FDA-Approved Finished Drugs
Four brand-name GLP-1 receptor agonist products dominate the conversation. Semaglutide is sold as Ozempic for type 2 diabetes management and as Wegovy for chronic weight management — both manufactured by Novo Nordisk. Tirzepatide is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management — both manufactured by Eli Lilly. Liraglutide is sold as Victoza (diabetes) and Saxenda (weight management) by Novo Nordisk.
These are FDA-approved finished drug products. The FDA reviewed and approved each specific formulation, dose strength, delivery device, and indication based on the manufacturer's clinical trial data. Manufacturing is conducted under FDA Current Good Manufacturing Practice (CGMP) regulations with full supply chain oversight.
The peer-reviewed clinical trial evidence for these products is substantial. The STEP trial program for semaglutide 2.4 mg reported average body weight reductions in the range of approximately 14.9% over 68 weeks in adults without type 2 diabetes. The SURMOUNT trials for tirzepatide 15 mg reported approximately 20.9% over 72 weeks. A 2026 systematic review across 22 randomized controlled trials with 41,757 individuals confirmed both molecules as effective for weight loss in patients with and without diabetes.
The trade-off is price. Cash-pay list prices for Wegovy and Zepbound have run above $1,000 per month at retail in the United States. Insurance coverage varies widely — many plans don't cover GLP-1 medications for weight management, only for diabetes. That gap is what created demand for the compounded category.
Compounded GLP-1 Medications: A Different Regulatory Framework
Compounding is the practice of preparing customized medications by combining or altering pharmaceutical ingredients to meet individual patient needs. It exists for legitimate reasons — patients with allergies to standard formulations, dose strengths not commercially available, alternative delivery routes, or pediatric customization.
The Federal Food, Drug, and Cosmetic Act recognizes two compounding categories.
Section 503A covers state-licensed pharmacies that compound patient-specific prescriptions. The model is typically: one prescription, one patient, one formulation. 503A operates primarily under state board of pharmacy regulation, not direct FDA premarket approval. The compounded product itself isn't FDA-approved as a finished drug — it's compounded based on a specific patient prescription.
Section 503B covers outsourcing facilities — larger-scale compounders that register with the FDA and operate under federal oversight. 503B facilities can produce compounded medications in batch quantity, including for office stock and provider distribution. They operate under requirements closer to (but not equivalent to) full pharmaceutical manufacturing.
The legal pathway for either category to compound copies of an FDA-approved drug is narrow. Generally, a 503A or 503B compounder may produce a copy only when (a) the FDA-approved product appears on the FDA's drug shortage list, or (b) for 503B specifically, the bulk active pharmaceutical ingredient is on the FDA's 503B bulks list, indicating clinical need.
For semaglutide and tirzepatide, both pathways were active during the 2022–2024 shortage period. Demand outstripped Novo Nordisk and Eli Lilly's manufacturing capacity. The FDA placed both molecules on the shortage list. Compounding pharmacies — both 503A and 503B — moved to fill the gap, often at $150 to $300 per month versus $1,000+ for the brand-name products. The scale was significant. By October 2025, IQVIA reporting indicated more than 80% of compounded semaglutide and tirzepatide prescriptions included supplemental ingredients (B vitamins, levocarnitine), which compounders cited as evidence of customization beyond simple copying — and which the FDA viewed with skepticism.
What Changed: The Wind-Down and the April 30, 2026 Proposal
The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025. Both removals triggered phased enforcement deadlines for compounders to wind down operations. The Outsourcing Facilities Association filed federal lawsuits challenging both determinations. Courts denied preliminary injunctions in both cases. The wind-down deadlines held.
That left one remaining structural question for 503B compounding of these GLP-1 molecules: would the FDA add semaglutide, tirzepatide, or liraglutide to the 503B bulks list, which would have created an alternative legal pathway for ongoing 503B compounding regardless of shortage status?
The April 30, 2026 proposal answers that question. The FDA explicitly determined there is no clinical need to include any of the three molecules on the 503B bulks list. Per FDA Commissioner Marty Makary, MD, MPH, in the agency's announcement: “When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need.”
The proposal is open for public comment through June 29, 2026, after which the FDA will consider submissions before issuing a final determination. If finalized, it formally closes the 503B pathway for bulk compounding of semaglutide, tirzepatide, and liraglutide — even in the event of a future shortage designation.
Patient safety data played a role. As of early 2025, the FDA had received over 455 adverse event reports linked to compounded semaglutide and over 320 linked to compounded tirzepatide. Many involved dosing errors from patients self-administering incorrect amounts from multidose vials, with some requiring hospitalization. Concerns about counterfeit products entering the market through online channels reinforced the agency's enforcement posture. We cover the side effect profile and Novi's specific patient safety mechanics in our side effects and cancellation policy review.
What This Means for 503A Compounding
The April 30 proposal targets 503B specifically. The 503A pathway — patient-specific compounding by state-licensed pharmacies — operates under a different statutory framework that doesn't depend on the 503B bulks list. As of early May 2026, 503A pharmacies continue to compound patient-specific prescriptions for semaglutide, tirzepatide, and liraglutide where state law permits and where the prescribing relationship is legitimate.
That said, the 503A pathway has its own constraints. 503A compounding is supposed to be patient-specific — produced for an individual patient on the basis of a specific prescription, not produced in bulk for office stock or undifferentiated patient populations. The “essentially a copy” doctrine — under which a compounder cannot legally produce a near-duplicate of an available FDA-approved drug — applies to both pathways. The line between legitimate 503A compounding and impermissible mass production is one the FDA, state pharmacy boards, and courts have been actively defining.
The practical implication: telehealth platforms historically supplied by 503B outsourcing facilities have already begun adapting. Some have shifted toward 503A pharmacy partnerships. Others have begun pivoting toward brand-name medication access at brand-name prices. Some have announced exits from the compounded GLP-1 category entirely.
Where Novi Sits in This Framework
Novi's published terms describe sourcing from “trusted, licensed U.S. pharmacies” and reference “pharmacy network providers” without naming specific partners or specifying 503A versus 503B status. The platform's marketing emphasizes that medications are “authentic and sourced from trusted, licensed U.S. pharmacies,” with quality and safety standards.
That's a transparency gap that prospective patients can close by asking. Specific questions that yield useful answers:
Are Novi's pharmacy partners 503A state-licensed pharmacies, 503B outsourcing facilities, or both? If 503B, are those facilities adapting their sourcing in light of the April 30, 2026 proposal? Does the platform plan to continue compounded sourcing if and when the proposal is finalized? Will pricing change if sourcing shifts? Are certificates of analysis (sterility, endotoxin, potency) available on request? Is the active ingredient semaglutide free base or sodium versus semaglutide acetate? (Acetate forms are not used in FDA-approved finished products and have been associated with quality concerns.)
These questions are answerable by support@joinnovi.com. The platforms that answer them clearly are differentiating themselves. The platforms that don't, in the current regulatory environment, are accepting transparency risk that prospective patients should weigh in their decision. Our broader analysis of how Novi compares against other platforms on disclosure and pharmacy network transparency is in the Novi vs SynergyRx vs TeleHealth Med comparison.
The Clinical Equivalence Question
A common claim in compounded-GLP-1 marketing — including some of Novi's marketing language — is that compounded versions contain “the same active ingredient as” the brand-name drug. This is technically defensible at the chemical level when the bulk API is genuine semaglutide free base or sodium produced to USP standards. It is not the same statement as saying the products are clinically equivalent.
FDA-approved finished products go through bioequivalence and clinical trial documentation that compounded versions don't. The finished formulation — the inactive ingredients, the buffer system, the delivery device, the manufacturing controls — affects pharmacokinetics, stability, and reproducibility. Two products with the same active ingredient at the same nominal dose may not deliver identical clinical outcomes if the finished formulation differs materially.
The published peer-reviewed efficacy data for semaglutide and tirzepatide — the 14.9% and 20.9% body-weight-reduction figures from the STEP and SURMOUNT trials — was generated using brand-name FDA-approved finished products. Whether and to what extent compounded versions deliver comparable outcomes hasn't been studied in equivalent trials. Treat outcome expectations on compounded versions as uncertain in a way they aren't with brand-name products.
For the broader pricing context that drives the choice between categories, see our Novi cost analysis.
What a Reasonable Decision Framework Looks Like
For a prospective patient evaluating compounded versus brand-name GLP-1 access through Novi or any similar platform, a reasonable evaluation framework includes:
The clinical fit. Whether GLP-1 therapy is medically appropriate, given BMI, comorbidities, contraindications, and goals. This is determined with a licensed clinician, not from a marketing page.
The regulatory fit. Whether the platform's pharmacy network operates under 503A or 503B, and whether the platform is positioned to adapt if the FDA proposal is finalized. Platforms that aren't transparent on this dimension carry more uncertainty than platforms that are.
The financial fit. Whether brand-name access through insurance is feasible (some plans cover Wegovy or Zepbound; many require prior authorization, BMI documentation, and step therapy). Whether brand-name cash-pay pricing is feasible. Whether the compounded-medication price point with a 3-month commitment is the right structure for the patient's situation.
The transparency fit. How the platform answers diligence questions. Whether certificates of analysis are available. Whether named pharmacy partners are disclosed.
The full picture of what to evaluate before signing up with Novi specifically is covered in our core Novi review.
Bottom Line
The compounded versus brand distinction matters more in May 2026 than it did in March 2026. The April 30 FDA proposal is a clear signal of regulatory direction. Compounded GLP-1 access through 503B facilities is being closed. 503A patient-specific compounding remains, but with constraints. Brand-name access remains the option with the strongest regulatory standing and the most clinical trial documentation.
For a prospective Novi patient: the platform's compounded-GLP-1 offering is real, available, and competitively priced. The 3-month commitment is the contractual structure. The pharmacy network and 503A/503B status is the question that determines how stable that offering is over the coming months. Ask before you sign.
The FDA's comment window closes June 29, 2026. By that date, the regulatory shape of this category becomes substantially clearer. Patients making decisions before then are making them under genuine regulatory uncertainty — and any honest review should say that out loud.